Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release Market – View in Detailed Research Report

MARKET INSIGHTS

Global Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release Market size was valued at USD 0.75 billion in 2025. The market will grow from USD 0.81 billion in 2026 to USD 1.50 billion by 2034, showing a CAGR of 7.5 % during the forecast period.

Poly(Lactic-co-Glycolic Acid) (PLGA) microspheres are a versatile biodegradable polymer platform engineered for controlled drug release. Encapsulation within a hydrolytically degradable matrix yields predictable, sustained release over weeks to months, underpinning long‑acting injectable formulations that improve patient adherence by reducing dosing frequency while maintaining steady therapeutic levels.

Steady expansion is spurred by the pharmaceutical industry’s move toward advanced drug delivery systems that overcome the limitations of immediate‑release medicines. PLGA microspheres deliver key advantages—biocompatibility, tunable degradation through lactic‑to‑glycolic acid ratio adjustments, and protection of sensitive molecules such as peptides and proteins from rapid degradation. Growing demand for chronic‑condition therapies in oncology, hormone therapy, and central nervous system disorders has accelerated adoption. Commercial successes such as Lupron Depot and Risperdal Consta demonstrate the platform’s clinical reliability and commercial viability, with multiple products generating significant revenues annually. Leading players are investing in formulation innovations and manufacturing scale‑up to support an expanding pipeline of long‑acting injectable candidates.

Top 10 Companies in the PLGA Microsphere for Controlled Drug Release Market (2026)

🔟 1. Evonik Industries AG

Headquarters: Essen, Germany
Key Offering: RESOMER® PLGA polymers for long‑acting drug delivery

Evonik’s RESOMER® portfolio offers a range of polymer grades with precise lactic‑to‑glycolic ratios and controlled molecular weights, enabling fine‑tuned degradation kinetics for injectable microspheres. The company’s GMP‑compliant manufacturing facilities and robust quality management system provide a reliable supply chain for pharmaceutical developers seeking consistency across clinical batches.

Sustainability & Growth Initiatives:

• Investment in green polymer synthesis to reduce carbon footprint.
• Collaboration with academic partners on next‑generation PLGA formulations.
• Expansion of production capacity in Europe and North America.

9️⃣ 2. Corbion NV

Headquarters: Utrecht, Netherlands
Key Offering: PURASORB® PLGA grades for controlled release

Corbion’s PURASORB® range delivers high‑purity PLGA polymers with customizable lactide‑glycolide ratios, supporting both high‑drug‑loading and low‑burst formulations. The company’s integrated supply chain—from raw material sourcing to finished polymer—ensures traceability and compliance with stringent regulatory requirements.

Sustainability & Growth Initiatives:

• Development of bio‑based monomers to lower dependency on petroleum feedstocks.
• Participation in circular economy pilots for polymer recycling.
• Strategic partnerships with biotech firms to co‑develop next‑generation delivery platforms.

8️⃣ 3. Oakwood Laboratories

Headquarters: Westlake Village, United States
Key Offering: End‑to‑end PLGA microsphere technology for sustained‑release injectables

Oakwood specializes in formulation development, scale‑up, and manufacturing of PLGA microspheres for peptides, proteins, and small molecules. Its proprietary emulsion‑solvent evaporation and spray‑drying processes achieve high encapsulation efficiencies and controlled burst release.

Sustainability & Growth Initiatives:

• Implementation of energy‑efficient manufacturing lines.
• Adoption of process analytical technology (PAT) for real‑time quality control.
• Expansion of contract development services to support global biopharmaceuticals.

7️⃣ 4. Akina, Inc.

Headquarters: San Diego, United States
Key Offering: Tailored PLGA solutions for complex drug encapsulation

Akina offers a portfolio of PLGA polymers with adjustable end‑group chemistries, enabling formulation scientists to mitigate initial burst and enhance protein stability. The company also provides analytical services to characterize polymer degradation kinetics.

Sustainability & Growth Initiatives:

• Integration of renewable energy sources in manufacturing facilities.
• Development of scalable microfluidic encapsulation platforms.
• Collaboration with academic institutions on protein‑drug delivery research.

6️⃣ 5. Bezwada Biomedical, LLC

Headquarters: Woburn, United States
Key Offering: PLGA microsphere formulations for peptide and protein therapeutics

Bezwada focuses on protecting biologics from enzymatic degradation and preserving bioactivity through optimized polymer matrices. The company’s formulation expertise reduces immunogenicity risk and improves patient outcomes.

Sustainability & Growth Initiatives:

• Use of biodegradable excipients to lower environmental impact.
• Implementation of closed‑loop manufacturing processes.
• Strategic alliances with global pharma to expand product portfolio.

5️⃣ 6. Nomisma Healthcare Pvt. Ltd.

Headquarters: Mumbai, India
Key Offering: PLGA microsphere technology for affordable long‑acting injectables

Nomisma delivers cost‑effective PLGA solutions tailored for emerging markets. Its process optimization reduces particle‑size variability and enhances scalability.

Sustainability & Growth Initiatives:

• Investment in local polymer synthesis to support regional supply chains.
• Adoption of waste‑reduction protocols in production.
• Collaboration with Indian regulatory bodies to streamline approvals.

4️⃣ 7. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: Advanced PLGA polymers for controlled‑release drug delivery

Merck’s PLGA portfolio supports high‑precision release profiles for oncology and endocrine therapies. The company’s research arm focuses on next‑generation polymer chemistries that reduce burst release and improve drug stability.

Sustainability & Growth Initiatives:

• Carbon‑neutral manufacturing commitments.
• Investment in green chemistry for polymer synthesis.
• Collaborations with global pharma to accelerate pipeline development.

3️⃣ 8. Jinan Digang Bioengineering Co., Ltd.

Headquarters: Jinan, China
Key Offering: PLGA microsphere production for biopharmaceuticals

Jinan Digang supplies high‑grade PLGA polymers and offers contract manufacturing services for large‑scale production of long‑acting injectables. Its scalable processes support both generic and branded products.

Sustainability & Growth Initiatives:

• Implementation of water‑saving technologies.
• Development of digital twins for process optimization.
• Partnerships with Chinese pharma to expand market reach.

2️⃣ 9. Mitsui Chemicals

Headquarters: Tokyo, Japan
Key Offering: PLGA polymer grades for controlled‑release applications

Mitsui’s PLGA lines feature customizable lactide‑glycolide ratios and end‑group chemistries, supporting diverse therapeutic agents. The company emphasizes quality and regulatory compliance across its global facilities.

Sustainability & Growth Initiatives:

• Adoption of renewable energy in production.
• Research into biodegradable polymer recycling.
• Collaboration with Japanese regulatory agencies to streamline approvals.

1️⃣ 10. Biocon Ltd.

Headquarters: Bengaluru, India
Key Offering: PLGA microsphere technology for biologics and small‑molecule drugs

Biocon offers a portfolio of PLGA polymers and provides end‑to‑end development services for long‑acting formulations. The company’s focus on cost‑effective manufacturing makes it attractive to emerging‑market players.

Sustainability & Growth Initiatives:

• Use of renewable feedstocks for polymer synthesis.
• Implementation of waste‑to‑energy conversion in production.
• Strategic alliances with global pharma to expand product pipeline.

Download FREE Sample Report: Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release Market – View in Detailed Research Report

Get Full Report: Poly(Lactic-co-Glycolic Acid) (PLGA) Microsphere for Controlled Drug Release Market – View in Detailed Research Report

Outlook

Over the forecast horizon, the PLGA microsphere market is expected to consolidate around a handful of polymer suppliers and formulation technology providers. The region that will drive the most significant growth is North America, where robust R&D ecosystems and a mature regulatory framework create an enabling environment for rapid product translation. Asia‑Pacific is poised for accelerated uptake, supported by expanding biopharmaceutical manufacturing capacity and a growing pipeline of long‑acting injectable candidates.

Future Trends

Key trends that will shape the market include:

• Integration of microfluidic and coaxial electrospray techniques to achieve higher drug loading and tighter particle‑size control.
• Development of stimulus‑responsive PLGA formulations that release therapeutics in response to pH or temperature cues.
• Expansion of PLGA applications beyond traditional drug delivery into regenerative medicine, vaccine platforms, and gene‑therapy vectors.
• Increased focus on sustainability, with polymer manufacturers moving toward renewable feedstocks and closed‑loop manufacturing.